TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company’s Board of Directors.
“Ms. Chao’s appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders,” said Par Nijhawan, MD, Chief Executive Officer of Edesa.
Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. She is the founder of CoreStrategies Management, LLC, which provides corporate and financial consulting to biotech and life sciences companies. Ms. Chao currently serves as a Board Director of Endo International plc. and is a member of its Audit Committee and Compliance Committee. Prior to joining Endo, Ms. Chao served as a Director (since 2015) and as Board Chair (since October 2019) of BioSpecifics Technologies Corp. until its acquisition by Endo. In addition, since March 2022, she has been a board member of Cardiol Therapeutics Inc. and serves as Chair of Cardiol’s Corporate Governance and Compensation Committee.
Previously, Ms. Chao was Managing Director and Senior Lead Biotechnology Securities Analyst at Deutsche Bank. She was also a Managing Director and Senior Lead Biotechnology Analyst at RBC Capital Markets and a Senior Analyst in Biotechnology at Leerink Swann & Co. Ms. Chao was a research fellow at Massachusetts General Hospital/Harvard Medical School as a recipient of the BioMedical Research Career Award. She received her BA in Politics and Greek Classics from New York University.
“I am looking forward to working with the Board of Directors and the Edesa team in supporting Edesa’s strategic outlook for advancing important new treatments in the fields of immunotherapy and inflammatory disease, as the company continues to further its corporate, regulatory and commercial strategy,” said Ms. Chao.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among Covid-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors – at the inception of inflammation rather than after inflammation has occurred – Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.
About Bedford Group/TRANSEARCH
Bedford Group/TRANSEARCH is one of the Top 10 largest retained executive search firms in the world, with 60 offices in 40 countries. With North American Healthcare offices based in Toronto, Canada and Cambridge, Massachusetts, Bedford Group provides premium executive search and talent management solutions to a diverse group of healthcare clients, including start-ups, multi-nationals, publicly traded and private organizations. In addition to retained executive search, Bedford Group provides services in Succession Planning, Executive & Board Compensation, Culture, Organizational Strategy, Diversity and Inclusion, Leadership Assessment and Virtual Onboarding.
Darren Raycroft, Managing Director- North American Healthcare & Life Sciences
Howard Pezim, Managing Director- North American Healthcare & Life Sciences